alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States. Conventional therapies are unlikely to control advanced stage ovarian cancers, thus requiring innovative alternative therapies. In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, alpha-galactosylceramide (alpha-GalCer) using two different mouse models. Our data suggests that treatment with alpha-GalCer led to an increase in the IFN-gamma serum levels in the presence or absence of irradiated mouse ovarian surface epithelial tumor cells (MOSEC). Furthermore, administration of irradiated MOSEC tumor cells with adjuvant alpha-GalCer generated significant protective and therapeutic antitumor effects against MOSEC tumors in vaccinated C57BL/6 mice. In addition, immune cells expressing CD4, CD8 or NK1.1 markers were found to be important for the protective antitumor effects generated by irradiated tumor cell-based vaccines combined with adjuvant alpha-GalCer. We also found that treatment of a spontaneous ovarian cancer murine model, the Müllerian inhibiting substance type II receptor T antigen (TgMISIIR-TAg) transgenic mice with ovarian tumor cell-based vaccines combined with adjuvant alpha-GalCer led to prolonged survival as well as increased numbers of tumor-specific CD8+ T cells. Therefore, irradiated tumor cell-based vaccines in combination with alpha-GalCer are capable of breaking immune tolerance and generating significant antitumor effects in two different mouse tumor models. Our study serves as a foundation for future clinical translation.
Choi
Youn Seok
YS
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Hoory
Talia
T
Monie
Archana
A
Wu
Annie
A
Connolly
Denise
D
Hung
Chien-Fu
CF
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000528:radiation effects / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002470:Cell Survival; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005434:Flow Cytometry; D005699:Galactosylceramides / Q000494:pharmacology*; D007371:Interferon-gamma / Q000097:blood; D016131:Lymphocyte Subsets / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000517:prevention & control*; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D005699:Galactosylceramides; C493154:alpha-galactosylceramide; D007371:Interferon-gamma
Curr Opin Mol Ther. 1999 Feb;1(1):50-6
11249684
Oncol Res. 1995;7(10-11):529-34
8866665
Expert Opin Biol Ther. 2005 Sep;5(9):1193-210
16120050
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
10735013
Vaccine. 2007 Jan 2;25(1):127-35
16930783
J Immunol. 2005 Sep 1;175(5):3309-17
16116223
Gene Ther. 2007 Jun;14(12):921-9
17377599
Hum Gene Ther. 2007 Jul;18(7):575-88
17576157
J Immunol. 1998 Oct 1;161(7):3271-81
9759842
Cancer Res. 1998 Mar 15;58(6):1202-7
9515806
Eur J Immunol. 2001 Jun;31(6):1720-7
11385616
Vaccine. 2007 Jul 9;25(28):5189-98
17548137
Adv Exp Med Biol. 2007;601:345-55
17713023
Science. 1997 Nov 28;278(5343):1626-9
9374463
J Exp Med. 1998 Oct 19;188(8):1529-34
9782130
J Immunol. 2007 Mar 1;178(5):2853-61
17312129
Cancer Res. 2003 Mar 15;63(6):1389-97
12649204
Carcinogenesis. 2000 Apr;21(4):585-91
10753190
Immunol Rev. 2002 Oct;188:147-54
12445288
J Clin Invest. 2004 Dec;114(12):1800-11
15599405
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8
12960397
Nat Immunol. 2002 Sep;3(9):867-74
12154358
Gene Ther. 2007 Aug;14(16):1189-98
17581599
Blood. 2007 Sep 15;110(6):2013-9
17581919
Int Immunol. 2006 Aug;18(8):1279-83
16772371
J Immunol. 1997 Sep 1;159(5):2240-9
9278312